跳到内容
Endocannabinoid regulation of monoamines in psychiatric and neurological disorders 预览资料
关闭预览资料
正在查...

Endocannabinoid regulation of monoamines in psychiatric and neurological disorders

著者: Elisabeth J van Bockstaele
出版商: New York : Springer, ©2013.
版本/格式:   电子图书 : 文献 : 英语查看所有的版本和格式
数据库:WorldCat
提要:
The past two decades have seen a tremendous growth in knowledge related to cannabinoid receptor signaling in brain. In addition, the impact and consequences of cannabinoid modulation of monoaminergic circuits is steadily emerging demonstrating a significant interaction between these two systems in a variety of psychiatric (affective disorders) and neurological disorders (multiple sclerosis, pain). Despite increasing  再读一些...
评估:

(尚未评估) 0 附有评论 - 争取成为第一个。

主题
更多类似这样的

 

在线查找

与资料的链接

在图书馆查找

&AllPage.SpinnerRetrieving; 正在查找有这资料的图书馆...

详细书目

类型/形式: Electronic books
therapeutic use
drug therapy
附加的形体格式: Print version:
Endocannabinoid regulation of monoamines in psychiatric.
[S.l.] : Springer-Verlag New York, 2013
(OCoLC)841520677
材料类型: 文献, 互联网资源
文件类型: 互联网资源, 计算机文档
所有的著者/提供者: Elisabeth J van Bockstaele
ISBN: 9781461479406 1461479401
OCLC号码: 852471079
注意: Includes index.
描述: 1 online resource.
内容: Endocannabinoids and monoamines: modulating the modulators --
Endocannabinoid-mediated synaptic plasticity --
Current cannabinoid receptor nomenclature and pharmacological principles --
Cue-elicited craving for cannabis activates the reward neurocircuitry associated with the neuropathology of addiction --
Cannabinoid modulation of dopaminergic circuits in neurodegenerative and neuropsychiatric disorders --
Pathophysiology of mood disorders and mechanisms of action of antidepressants and mood stabilizers --
Anatomical, biochemical and behavioral evidence for cannabinoid modulation of noradrenergic circuits: role of norepinephrine in cannabinoid-induced aversion --
Gender Disparity of Depression: The Role of Endocannabinoids and Noradrenergic Function --
Endocannabinoids, Monoamines and Stress --
Chronic effects of cannabinoid drugs on monoaminergic systems and the role of endocannabinoids and cannabinoid receptors in human brain disorders --
Endocannabinoid Signaling and the Regulation of the Serotonin System --
Modulation of serotonin firing activity through CB1 agonists and FAAH inhibitors --
Involvement of serotonergic system in cannabinoid analgesia --
Cannabinoids, monoamines, COMT and schizophrenia: pathobiological mechanisms in psychosis.
责任: Elisabeth J. van Bockstaele, editor.
更多信息:

摘要:

Endocannabinoid Regulation of Monoamines in Psychiatric and Neurological Disorders  再读一些...

评论

社评

出版商概要

From the reviews: "This book reviews the expansion of our understanding of cannabinoid modulation of monoaminergic circuits and their interactions in a variety of psychiatric and neurological 再读一些...

 
用户提供的评论
正在获取GoodReads评论...
正在检索DOGObooks的评论

标签

争取是第一个!
确认申请

你可能已经申请过这份资料。如果还是想申请,请选确认。

链接数据


<http://www.worldcat.org/oclc/852471079>
library:oclcnum"852471079"
library:placeOfPublication
library:placeOfPublication
owl:sameAs<info:oclcnum/852471079>
rdf:typeschema:Book
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:bookFormatschema:EBook
schema:contributor
schema:copyrightYear"2013"
schema:datePublished"2013"
schema:description"The past two decades have seen a tremendous growth in knowledge related to cannabinoid receptor signaling in brain. In addition, the impact and consequences of cannabinoid modulation of monoaminergic circuits is steadily emerging demonstrating a significant interaction between these two systems in a variety of psychiatric (affective disorders) and neurological disorders (multiple sclerosis, pain). Despite increasing evidence from preclinical data suggesting that therapeutic use of cannabinoid-based drugs may outweigh any potential risks in certain serious medical conditions, the debate surrounding its widespread utility continues as regulatory concerns preclude a smooth transition of promising preclinical studies into clinical trial testing. This may persist in the near future as state and federal governments debate over regulation of medicinal applications of cannabis. Applications for medicinal cannabinoids that are already under investigation include the treatment of nausea, anorexia, neurodegeneration, inflammation, excitotoxicity and pain. The appetitive and anti-emetic properties of cannabinoids have led to the approval of their use in chemotherapy and AIDS patients. There is growing evidence for therapeutic cannabinoid effects on inflammatory and excitotoxic cellular processes that are linked to epilepsy, Parkinson's disease, amyotrophic lateral sclerosis, spasticity, and central nervous system injury. The chapters, herein, review and discuss current insights into the brain endocannabinoid system, cannabinoid receptor signaling on synaptic plasticity, potential therapeutic applications with a particular focus on endocannabinoid modulation of dopaminergic, noradrenergic and serotonergic circuitry. The potential for establishing cannabinoid-monoaminergic interactions as a novel target in the development of improved treatment strategies for psychiatric and neurological disorders is promising and will require future clinical studies to determine whether promising pre-clinical findings translate into new therapies."
schema:description"Endocannabinoids and monoamines: modulating the modulators -- Endocannabinoid-mediated synaptic plasticity -- Current cannabinoid receptor nomenclature and pharmacological principles -- Cue-elicited craving for cannabis activates the reward neurocircuitry associated with the neuropathology of addiction -- Cannabinoid modulation of dopaminergic circuits in neurodegenerative and neuropsychiatric disorders -- Pathophysiology of mood disorders and mechanisms of action of antidepressants and mood stabilizers -- Anatomical, biochemical and behavioral evidence for cannabinoid modulation of noradrenergic circuits: role of norepinephrine in cannabinoid-induced aversion -- Gender Disparity of Depression: The Role of Endocannabinoids and Noradrenergic Function -- Endocannabinoids, Monoamines and Stress -- Chronic effects of cannabinoid drugs on monoaminergic systems and the role of endocannabinoids and cannabinoid receptors in human brain disorders -- Endocannabinoid Signaling and the Regulation of the Serotonin System -- Modulation of serotonin firing activity through CB1 agonists and FAAH inhibitors -- Involvement of serotonergic system in cannabinoid analgesia -- Cannabinoids, monoamines, COMT and schizophrenia: pathobiological mechanisms in psychosis."
schema:exampleOfWork<http://worldcat.org/entity/work/id/1411312578>
schema:genre"Electronic books."
schema:inLanguage"en"
schema:name"Endocannabinoid regulation of monoamines in psychiatric and neurological disorders"
schema:publisher
schema:url<http://site.ebrary.com/id/10733550>
schema:url<http://dx.doi.org/10.1007/978-1-4614-7940-6>
schema:url
schema:url<http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=606343>
schema:url<http://lib.myilibrary.com?id=517034>
schema:workExample

Content-negotiable representations

关闭窗口

请登入WorldCat 

没有张号吗?很容易就可以 建立免费的账号.